Is Johnson & Johnson a good investment?
Johnson & Johnson (JNJ) is currently trading at 285.75 USD.
Market analysts have a consensus price target of 279.41 USD.
This suggests the asset is currently trading above analyst expectations.
In terms of valuation, the stock trades at a P/E ratio of 42.61.
This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule:
Johnson & Johnson is expected to release its next earnings report on Jan. 20, 2027.
The market consensus estimate for Forward EPS is 11.62.
For income investors, Johnson & Johnson pays a dividend yield of 1.94%.
With a payout ratio of 79%, the dividend appears
to be under pressure.
Company Profile
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Community Discussion